Cargando…
Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity
T cell-invigorating cancer immunotherapies have near-curative potential. However, their clinical benefit is currently limited, as only a fraction of patients respond, suggesting that these regimens may benefit from combination with tumor-targeting treatments. As oncogenic progression is accompanied...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
National Academy of Sciences
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511047/ https://www.ncbi.nlm.nih.gov/pubmed/31019077 http://dx.doi.org/10.1073/pnas.1814932116 |